Prudent tactics to sail the boat of PARP inhibitors as therapeutics for diverse malignancies

Expert Opin Drug Discov. 2023 Jul-Dec;18(10):1169-1193. doi: 10.1080/17460441.2023.2241818. Epub 2023 Jul 31.


Introduction: PARP inhibitors block the DNA-repairing mechanism of PARP and represent a promising class of anti-cancer therapy. The last decade has witnessed FDA approvals of several PARP inhibitors, with some undergoing advanced-stage clinical investigation. Medicinal chemists have invested much effort to expand the structure pool of PARP inhibitors. Issues associated with the use of PARP inhibitors that make their standing disconcerting in the pharmaceutical sector have been addressed via the design of new structural assemblages.

Area covered: In this review, the authors present a detailed account of the medicinal chemistry campaigns conducted in the recent past for the construction of PARP1/PARP2 inhibitors, PARP1 biased inhibitors, and PARP targeting bifunctional inhibitors as well as PARP targeting degraders (PROTACs). Limitations associated with FDA-approved PARP inhibitors and strategies to outwit the limitations are also discussed.

Expert opinion: The PARP inhibitory field has been rejuvenated with numerous tractable entries in the last decade. With numerous magic bullets in hand coupled with unfolded tactics to outwit the notoriety of cancer cells developing resistance toward PARP inhibitors, the dominance of PARP inhibitors as a sagacious option of targeted therapy is highly likely to be witnessed soon.

Keywords: BRCA mutations; DNA damage repair; PARP inhibitors; PROTACs; cancer; multitargeting agents.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • DNA Repair
  • Humans
  • Neoplasms* / drug therapy
  • Neoplasms* / pathology
  • Poly(ADP-ribose) Polymerase Inhibitors* / pharmacology
  • Poly(ADP-ribose) Polymerase Inhibitors* / therapeutic use


  • Poly(ADP-ribose) Polymerase Inhibitors